Welcome to our dedicated page for Healthequity SEC filings (Ticker: HQY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The HealthEquity, Inc. (NASDAQ: HQY) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. HealthEquity is an administrator and custodian of health savings accounts (HSAs) and other consumer-directed benefits, and its filings offer detailed information on financial performance, governance, capital allocation, and risk factors associated with this business.
Investors can review current reports on Form 8-K, which HealthEquity uses to report material events such as quarterly financial results and outcomes of the annual meeting of stockholders. For example, an 8-K dated September 2, 2025 references a press release with financial results, while an 8-K dated June 26, 2025 describes shareholder voting on director elections, auditor ratification, and advisory approval of executive compensation, as well as authorization of a common stock repurchase program.
In addition to 8-Ks, HealthEquity’s periodic reports (such as Forms 10-K and 10-Q, when accessed through EDGAR) contain comprehensive financial statements, segment information, and discussions of revenue categories including service revenue, custodial revenue, and interchange revenue. These filings also describe non-GAAP measures like Adjusted EBITDA and non-GAAP net income, along with reconciliations to the most comparable GAAP measures and explanations of how management uses these metrics.
Filings further outline key risks, including competition in the healthcare and benefits administration industry, dependence on tax-advantaged HSAs and other consumer-directed benefits, cybersecurity and data privacy concerns, regulatory changes, and reliance on partners and third-party vendors. On Stock Titan, AI-powered tools can be applied to these documents to surface important sections, summarize lengthy disclosures, and help users quickly locate information on topics such as stock repurchase programs, custodial asset management, and governance decisions recorded in HealthEquity’s SEC reports.
HEALTHEQUITY, INC. director William Gassen filed an initial ownership report showing he holds 734 shares of the company’s common stock directly. This establishes his baseline equity stake as an insider. A footnote explains that each restricted stock unit represents one share of common stock.
The restricted stock units vest in full on the date of HealthEquity’s annual stockholder meeting in June 2026, with vested shares to be delivered to Gassen at that time. This structure ties part of his compensation to the company’s future performance and continued service through that meeting.
HEALTHEQUITY, INC. executive vice president and general counsel Delano Ladd reported two stock-based compensation transactions involving the company’s common stock. On March 25, 2026, he acquired 15,157 restricted stock units as a grant and 20,451 restricted stock units vested and converted into shares at no cash cost to him.
Each restricted stock unit represents the right to receive one share of common stock. The newly granted 15,157 units will vest 25% on April 1, 2027, with 6.25% vesting on the first day of each calendar quarter for the following twelve quarters. After these awards, Ladd directly holds 108,848 shares.
Gathright Michael reported acquisition or exercise transactions in this Form 4 filing.
HEALTHEQUITY, INC. reported that Chief Customer Officer Michael Gathright received a grant of 15,157 shares of common stock as an equity award. The award is in the form of restricted stock units, each representing one future share at no purchase price.
According to the vesting schedule, 25% of the initial award will vest on April 1, 2027, with 6.25% vesting on the first day of each calendar quarter for the following twelve quarters. After this grant, Gathright directly holds 42,163 shares of HealthEquity common stock.
HEALTHEQUITY, INC. founder and vice chairman Stephen Neeleman reported equity compensation awards rather than open‑market trades. On March 25, 2026, he received 15,915 restricted stock units, each representing one common share, with 25% vesting on April 1, 2027 and 6.25% quarterly for the next twelve quarters.
He also acquired 23,860 shares of common stock as restricted stock units that vested on March 25, 2026, bringing his directly held common shares to 150,519. Separate option holdings remain outstanding, covering additional shares at exercise prices of $41.28, $61.72 and $73.61 with expirations between 2027 and 2029.
Fiore Michael Henry reported acquisition or exercise transactions in this Form 4 filing.
HealthEquity, Inc. executive Michael Henry Fiore, EVP and Chief Commercial Officer, received a grant of 17,582 shares of common stock in the form of restricted stock units. Following this award, he directly holds 65,633 shares. The units vest 25% on April 1, 2027, then 6.25% each quarter for the next twelve quarters.
HEALTHEQUITY, INC. executive vice president and chief technology officer Elimelech Rosner reported stock-based compensation activity in the form of restricted stock units (RSUs). He received an award of 19,704 RSUs, each representing one share of common stock, with 25% vesting on April 1, 2027 and 6.25% vesting quarterly over the next twelve quarters.
Separately, 40,903 RSUs vested into common stock on March 25, 2026. Following these acquisitions, Rosner’s directly held common stock position reported in this filing is 104,275 shares.
HEALTHEQUITY, INC. reported that EVP & CFO James M. Lucania acquired 27,283 shares of common stock through a grant/award at no purchase price. These are restricted stock units, each representing one share. The award vests 25% on April 1, 2027, then 6.25% quarterly over the following twelve quarters. After this compensation grant, he directly holds 111,849 shares.
Cutler Scott reported acquisition or exercise transactions in this Form 4 filing.
HealthEquity, Inc. President and CEO Scott Cutler received an equity grant of 72,754 shares of common stock in the form of restricted stock units. The award was recorded at a price of $0.00 per share because it is compensation, not an open‑market purchase.
Each unit represents a contingent right to one share of common stock. The grant will vest over time, with 25% vesting on April 1, 2027, and 6.25% vesting on the first day of each calendar quarter for the following twelve quarters. After this grant, Cutler directly holds 182,574 shares of common stock, reflecting both existing ownership and the newly awarded units as reported.
HealthEquity Inc: Amendment No. 9 to a Schedule 13G/A was filed by The Vanguard Group reporting beneficial ownership of 0 shares of common stock, representing 0% of the class. The filing notes an internal realignment effective January 12, 2026, under SEC Release No. 34-39538, with certain Vanguard subsidiaries to report ownership separately.
HealthEquity, Inc. files its annual report highlighting its role as a leading U.S. provider of technology-enabled health savings and consumer-directed benefits. As of January 31, 2026, it administered 10.6 million HSAs with $36.5 billion in HSA Assets and 7.2 million complementary CDBs, totaling 17.8 million accounts.
The company generates revenue from service, custodial, and interchange fees, with custodial fees from HSA cash and Client-held funds contributing 48% of revenue in fiscal 2026. A 2025 acquisition of the BenefitWallet HSA portfolio added about 616,000 HSAs and $2.7 billion of HSA Assets for $425 million.
HealthEquity emphasizes proprietary cloud-based platforms, integrated partnerships with more than 200 Network Partners, and increasing use of AI tools. Key risks include reliance on tax advantages for HSAs, interest-rate sensitivity, partner and cybersecurity failures, growing fraud and ransomware threats, intense competition from large financial and healthcare firms, and evolving privacy, healthcare, and AI regulation.